SDC1 and pancreatic neoplasm: Syndecan-1 (CD138) was evaluated as a target for bimodal NIRF imaging and multispectral optoacoustic tomography (MSOT, also known as photoacoustic imaging) in an orthotopic in vivo model of pancreatic cancer [38].